Semaglutide, tirzepatide, and retatrutide explained without the hype, plus the mechanisms, the data, and the access problem nobody talks about.
Ozempic, Wegovy, Mounjaro, Zepbound, semaglutide, tirzepatide, retatrutide. It looks like a crowded field. It is not. Those are three molecules wearing different labels, built on the same underlying platform across three tiers of biological engineering.
Ozempic and Wegovy are both semaglutide. Mounjaro and Zepbound are both tirzepatide. The brand name usually just signals whether it is labeled for diabetes or for weight management. All of them are based on hormones you already produce when you eat. The drugs are engineered versions that last for days instead of minutes.
The one that started the wave. Pulls a single lever, GLP-1. The most studied and most prescribed option in the class, with the deepest safety data. Roughly 15% body weight loss in trials. Reliable and proven, the dependable option that gets you there.
The same platform with better engineering. Pulls two levers, GLP-1 and GIP. That second lever tends to mean stronger results and a smoother ride with less nausea. Around 21% body weight loss in trials. For most people, this is the sweet spot.
The first triple agonist. Pulls three levers, adding glucagon, which directly raises fat burning and energy expenditure. The strongest signal in the class so far, with trial data approaching 28% body weight loss. Still in trials and not yet approved.
All three are hormones your gut and pancreas already release when you eat. These drugs just make them last.
Released by your gut when you eat. It tells your brain you are full, signals insulin release, and slows stomach emptying. Your natural "I am done eating" signal. On its own it lasts about two minutes, which is the whole problem these drugs were built to solve.
Also released when you eat. Paired with GLP-1 it improves insulin sensitivity and how your body processes fat, and it tends to blunt the nausea. This is the second lever that makes tirzepatide smoother than semaglutide.
The third lever, and the difference-maker in retatrutide. It pushes the liver to release stored energy and raises overall energy expenditure. The other two help you eat less. This one also helps you burn more.
Each tier adds horsepower. Each tier also adds side-effect potential. The strongest dose is rarely the smartest one. In the retatrutide trials, lower and mid doses delivered most of the benefit with far fewer dropouts, and the harsher side effects scaled up sharply at the top dose. Less is often more.
The headline numbers are real and they are large. But the more interesting story is what these compounds do beyond the scale. Trial readouts have reported improvements in waist circumference, cholesterol markers, triglycerides, blood pressure, and inflammation markers, alongside the weight loss.
There is also a reframe happening in how medicine views obesity. Researchers increasingly describe it as a complex neurometabolic and signaling problem, not a simple willpower failure. These drugs work because they help correct that signaling. That shift in framing matters as much as any single number.
The gaunt, deflated look people associate with GLP-1s is not the drug evaporating muscle. It is bad lifestyle on top of the drug: no resistance training, low protein, and crashing weight far too fast while appetite is suppressed. The drug did not do that. The missing foundation did.
Eat enough protein. Lift weights two to four times a week. Lose weight at a steady, sustainable pace instead of crashing it. Do that and the large majority of what you lose is fat, and you keep your strength. A GLP-1 is a powerful tool, but it still needs a foundation under it.
This is the same principle as the rest of the site. The compound is an amplifier. Just hopping on a GLP-1 with no plan is putting a bandage on the real problem. Root-cause it: the diet and lifestyle habits underneath.
Criticizing someone for losing weight on a GLP-1 is like mocking a student for studying. It is pure moral superiority, and it usually comes loudest from people who are not in shape themselves.
If obesity is a signaling problem, then a tool that helps correct the signal is not cheating. It is using the best option available. There is nothing to apologize for, and the stigma is fading fast as people watch friends and family transform their health with these drugs.
Plenty of people genuinely benefit from doctor oversight, and a doctor-led route is the right call for most. But the optionality inside traditional healthcare is fundamentally broken, and that information gap is exactly what 9th Life exists to close.
GLP-1 medications carry real side effects, and retatrutide in particular is still in clinical trials and not FDA approved. This page explains the class and the landscape. It is not a recommendation to start any medication. Talk to a qualified clinician and get bloodwork before considering a GLP-1.
A consultation can help you think it through and point you toward the right medical oversight.